Quadrant Capital Group LLC Genmab A/S Transaction History

Quadrant Capital Group LLC

$1.42 Billion
Q3 2024

A detailed history of Quadrant Capital Group LLC transactions in Genmab A/S stock. As of the latest transaction made, Quadrant Capital Group LLC holds 8,270 shares of GMAB stock, worth $173,421. This represents 0.01% of its overall portfolio holdings.

Number of Shares

8,270

Previous 6,308 31.1%

Holding current value

$173,421

Previous $158,000 27.22%

% of portfolio

0.01%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$23.84 - $28.48 $46,774 - $55,877	1,962 Added 31.1%	8,270 $201,000
Q2 2024 Aug 12, 2024	SELL	$25.13 - $30.27 $14,298 - $17,223	-569 Reduced 8.27%	6,308 $158,000
Q1 2024 May 15, 2024	SELL	$26.43 - $32.77 $1,110 - $1,376	-42 Reduced 0.61%	6,877 $205,000
Q4 2023 Feb 08, 2024	SELL	$27.94 - $35.44 $79,656 - $101,039	-2,851 Reduced 29.18%	6,919 $220,000
Q3 2023 Nov 14, 2023	BUY	$35.27 - $42.24 $88,033 - $105,431	2,496 Added 34.31%	9,770 $344,000
Q2 2023 Aug 09, 2023	BUY	$37.4 - $42.94 $38,522 - $44,228	1,030 Added 16.5%	7,274 $276,000
Q1 2023 May 11, 2023	SELL	$34.88 - $43.22 $85,874 - $106,407	-2,462 Reduced 28.28%	6,244 $235,000
Q4 2022 Feb 10, 2023	BUY	$33.8 - $47.06 $49,415 - $68,801	1,462 Added 20.18%	8,706 $368,000
Q3 2022 Nov 10, 2022	BUY	$31.52 - $373.61 $96,167 - $1.14 Million	3,051 Added 72.76%	7,244 $233,000
Q2 2022 Aug 09, 2022	SELL	$26.83 - $38.57 $5,419 - $7,791	-202 Reduced 4.6%	4,193 $136,000
Q1 2022 May 06, 2022	SELL	$30.95 - $39.68 $5,849 - $7,499	-189 Reduced 4.12%	4,395 $159,000
Q4 2021 Feb 01, 2022	SELL	$35.87 - $47.12 $27,978 - $36,753	-780 Reduced 14.54%	4,584 $181,000
Q3 2021 Nov 12, 2021	BUY	$41.55 - $48.72 $15,872 - $18,611	382 Added 7.67%	5,364 $234,000
Q2 2021 Aug 09, 2021	SELL	$32.88 - $44.57 $295 - $401	-9 Reduced 0.18%	4,982 $203,000
Q1 2021 May 12, 2021	BUY	$30.92 - $44.4 $21,705 - $31,168	702 Added 16.37%	4,991 $164,000
Q4 2020 Feb 16, 2021	BUY	$33.66 - $40.76 $7,876 - $9,537	234 Added 5.77%	4,289 $174,000
Q3 2020 Nov 13, 2020	BUY	$33.07 - $38.68 $55,557 - $64,982	1,680 Added 70.74%	4,055 $148,000
Q2 2020 Aug 13, 2020	SELL	$20.05 - $33.89 $203,066 - $343,237	-10,128 Reduced 81.0%	2,375 $80,000
Q1 2020 May 15, 2020	SELL	$17.15 - $25.22 $17,956 - $26,405	-1,047 Reduced 7.73%	12,503 $265,000
Q4 2019 Feb 03, 2020	BUY	$18.88 - $24.14 $27,073 - $34,616	1,434 Added 11.84%	13,550 $296,000
Q3 2019 Oct 24, 2019	BUY	$18.0 - $21.38 $1,764 - $2,095	98 Added 0.82%	12,116 $241,000
Q2 2019 Jul 24, 2019	BUY	$16.37 - $18.47 $90,460 - $102,065	5,526 Added 85.12%	12,018 $219,000
Q1 2019 Apr 29, 2019	BUY	$14.53 - $17.93 $49,256 - $60,782	3,390 Added 109.28%	6,492 $111,000
Q4 2018 Jan 17, 2019	BUY	$12.12 - $16.48 $26,421 - $35,926	2,180 Added 236.44%	3,102 $49,000
Q3 2018 Oct 29, 2018	BUY	$15.23 - $17.96 $12,519 - $14,763	822 Added 822.0%	922 $88,000
Q2 2018 Aug 09, 2018	BUY	$14.78 - $21.54 $1,138 - $1,658	77 Added 334.78%	100 $1,000
Q1 2018 May 10, 2018	BUY	$16.76 - $21.68 $385 - $498	23 New	23 $1,000

Others Institutions Holding GMAB

# of Institutions

234

Shares Held

52.5M

Call Options Held

10.2K

Put Options Held

25.5K

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.8B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.

Account

Quadrant Capital Group LLC Genmab A/S Transaction History